精优药业预计财年录得未变现亏损8-8.5亿港元,主要涉Starcoin集团可换股债券等

美股速递
Jun 23

精优药业预计,在截至2024年3月31日的财政年度,将录得约8亿至8.5亿港元的未变现亏损。此项亏损主要源于对Starcoin集团可换股债券及其他金融资产投资的公允价值变动。

公司指出,相关公允价值评估是基于管理层在报告期末可获得的信息及假设。最终财务数据将以公司经审核的年度业绩公告为准。

此次预计亏损为非现金项目,不会对集团当前现金流及营运构成即时影响。精优药业强调,集团主营业务维持正常。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10